Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 22

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 22
---

should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.

You should carefully read
this prospectus, the documents that we incorporate by reference into this prospectus and the documents we reference in this prospectus
and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that
our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus
by these cautionary statements.

<div align='center'>12</div>

Except as required by law,
we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially
from those anticipated in any forward-looking statements, whether as a result of new information, future events or otherwise.

<div align='center'>13

USE OF PROCEEDS</div>

Except as described in any
prospectus supplement or in any related free writing prospectus that we may authorize to be provided to you, we currently intend to use
the net proceeds from the sale of securities under this prospectus for general corporate purposes, including manufacturing expenses, clinical
trial expenses, research and development expenses and general and administrative expenses. We may also use a portion of the net proceeds
to in-license, invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current
plans, commitments or agreements with respect to any acquisitions. As of the date of this prospectus, we cannot specify with certainty
all of the particular uses of the proceeds from the sale of securities under this prospectus. Accordingly, we will retain broad discretion
over the use of such proceeds. Pending the use of the net proceeds from the sale of securities under this prospectus as described above,
we intend to invest the net proceeds in investment-grade, interest-bearing instruments.

<div align='center'>14

DESCRIPTION OF CAPITAL STOCK</div>

Our articles of
incorporation authorize us to issue up to 217,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of
preferred stock, par value $0.01 per share. As of August 11, 2025, we had 36,229,842 shares of common stock outstanding and no shares
of preferred stock outstanding.

The following summary description
of our capital stock is based on the provisions of our articles of incorporation and by